Cure rates for acute lymphoblastic leukemia (ALL) have improved dramatically, but the incidence of avascular necrosis (AVN) has increased over the past decade. No national administrative data on the incidence of AVN or surgical therapies for AVN exist. We sought to define the incidence of AVN and AVN surgical interventions after treatment for ALL in a national administrative data set.

The Pediatric Health Information System (PHIS) is an administrative database including ICD-9 discharge diagnosis, procedure codes, and billing data for daily resource utilization from 43 free standing pediatric hospitals in the US. This study identified patients with an associated ICD-9 code for AVN (733.4X) in a cohort previously established by our group to have newly diagnosed ALL.

Between January 1999 and September 2011 242(2.25%), of the 10,729 patients in the ALL cohort had at least one admission with AVN with a mean time of 1.6 years from first ALL treatment until a hospital admission with an associated AVN diagnosis. Table 1 compares demographic and treatment characteristics between ALL patients with and without AVN diagnosis. Age 10-18.99 years and prednisone exposure during ALL induction were associated with increased incidence of AVN. Dexamethasone exposure was associated with a decreased incidence of AVN. AVN diagnosis was associated with a statistically significant increase in mortality. The rate of surgical intervention was 13.7%. The type and location of surgical intervention are reported in Table 2.

Table 1

Demographics

n (%)ALL Patients w/o AVN (n=10,487)
ALL Patients with AVN (n=242)
P
Age     <.0001M 
 <1 year 295 (2.8) (0.0)  
 1 to <10 years 7,515 (71.7) 65 (26.9)  
 10 to <19 years 2,557 (24.4) 169 (69.8)  
 ≥ 19 years 120 (1.1) (3.3)  
Sex     0.2009 
 Male 5,893 (56.2) 126 (52.1)  
 Female 4,594 (43.8) 116 (47.9)  
Race     0.1219 
 White 7,927 (75.6) 193 (79.8)  
 Black 774 (7.4) 17 (7.0)  
 Asian 321 (3.1) (2.1)  
 Native American 121 (1.2) (2.5)  
 Other 1,019 (9.7) 14 (5.8)  
 Missing 325 (3.1) (2.9)  
Region     0.0527 
 Midwest 2,742 (26.2) 63 (26.0)  
 Northeast 1,042 (9.9) 19 (7.9)  
 South 3,478 (33.2) 67 (27.7)  
 West 3,225 (30.8) 93 (38.4)  
Medication use during induction*      
Prednisone 4,252 (40.6) 152 (62.8) <.0001 
Pegasparaginase 6,540 (62.4) 150 (62.0) 0.9041 
Dexamethasone 6,378 (60.8) 104 (43.0) <.0001 
Concurrent Dex & Pred 600 (5.7) 17 (7.0) 0.3892 
Death 649 (6.2) 27 (11.2) 0.0017 
n (%)ALL Patients w/o AVN (n=10,487)
ALL Patients with AVN (n=242)
P
Age     <.0001M 
 <1 year 295 (2.8) (0.0)  
 1 to <10 years 7,515 (71.7) 65 (26.9)  
 10 to <19 years 2,557 (24.4) 169 (69.8)  
 ≥ 19 years 120 (1.1) (3.3)  
Sex     0.2009 
 Male 5,893 (56.2) 126 (52.1)  
 Female 4,594 (43.8) 116 (47.9)  
Race     0.1219 
 White 7,927 (75.6) 193 (79.8)  
 Black 774 (7.4) 17 (7.0)  
 Asian 321 (3.1) (2.1)  
 Native American 121 (1.2) (2.5)  
 Other 1,019 (9.7) 14 (5.8)  
 Missing 325 (3.1) (2.9)  
Region     0.0527 
 Midwest 2,742 (26.2) 63 (26.0)  
 Northeast 1,042 (9.9) 19 (7.9)  
 South 3,478 (33.2) 67 (27.7)  
 West 3,225 (30.8) 93 (38.4)  
Medication use during induction*      
Prednisone 4,252 (40.6) 152 (62.8) <.0001 
Pegasparaginase 6,540 (62.4) 150 (62.0) 0.9041 
Dexamethasone 6,378 (60.8) 104 (43.0) <.0001 
Concurrent Dex & Pred 600 (5.7) 17 (7.0) 0.3892 
Death 649 (6.2) 27 (11.2) 0.0017 

** Induction is defined as 60-day period from ALL admission

Table 2

Surgical Interventions during first AVN admission

DescriptionPatient count
Excision of lesion or tissue of femur 10 
Bone graft of femur 
Arthroscopy of knee 
Total hip replacement 
Arthrotomy of knee 
Excision or destruction of lesion of hip joint 
Wedge osteotomy of femur 
Excision of lesion or tissue of tibia and fibula 
Excision of other bone for graft 
Bone graft of tibia and fibula 
Arthrotomy of hip 
Repair of knee 
Partial hip replacement 
Excision of elbow joint 
Excision of lesion or tissue of humerus 
Excision of femur for graft 
Partial ostectomy of femur 
Bone graft of humerus 
Arthrotomy of elbow 
Arthrotomy of other specified site 
Arthroscopy of hip 
Excision or destruction of lesion of elbow joint 
Excision or destruction of lesion of knee joint 
Excision or destruction of lesion of ankle joint 
DescriptionPatient count
Excision of lesion or tissue of femur 10 
Bone graft of femur 
Arthroscopy of knee 
Total hip replacement 
Arthrotomy of knee 
Excision or destruction of lesion of hip joint 
Wedge osteotomy of femur 
Excision of lesion or tissue of tibia and fibula 
Excision of other bone for graft 
Bone graft of tibia and fibula 
Arthrotomy of hip 
Repair of knee 
Partial hip replacement 
Excision of elbow joint 
Excision of lesion or tissue of humerus 
Excision of femur for graft 
Partial ostectomy of femur 
Bone graft of humerus 
Arthrotomy of elbow 
Arthrotomy of other specified site 
Arthroscopy of hip 
Excision or destruction of lesion of elbow joint 
Excision or destruction of lesion of knee joint 
Excision or destruction of lesion of ankle joint 

To our knowledge, this is the first report using a national administrative database to determine the incidence of AVN in ALL. As expected, age was associated with AVN risk. The association of increased in-hospital mortality was unexpected and warrants further study. Surgical interventions typically involved lower extremity procedures. Work is ongoing to define the rates of subsequent surgical procedures and complication rates. These data demonstrate the feasibility of using administrative data to study surgical interventions for patients with AVN.

Disclosures:

Rheingold:Novartis: Research Funding.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution